Empfehlungen für die Anwendung der Immunapherese bei der Therapie bullöser Autoimmundermatosen
Detlef Zillikens(University of Lübeck), Fabian Ziller(Vivantes Klinikum), Rüdiger Eming(Philipps University of Marburg), Iakov Shimanovich(University of Lübeck), Michael Hertl(Universitätsklinikum Gießen und Marburg), Gerhard Fierlbeck(Humboldt-Universität zu Berlin), Ocko Kautz, Franz Karlhofer(Medical University of Vienna), Sven Quist(University Hospital Magdeburg), Kurt Derfler(University of Vienna), Enno Schmidt(Carrier (United States)), Silke Hofmann(Helios Universitätsklinikum Wuppertal), Matthias Goebeler(University of Würzburg), Michael Michael(Ospedale San Donato), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Martin Nitschke(University Hospital Schleswig-Holstein), Stefan Schanz(University of Tübingen), Andreas Opitz(University of Würzburg)
JDDG Journal der Deutschen Dermatologischen Gesellschaft
October 1, 2007
Cited by 0
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586
Adjunctive Systemic Hyperbaric Oxygen Therapy in Treatment of Severe Prevalently Ischemic Diabetic Foot Ulcer: A randomized study
|Diabetes Care|1996|392
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|370